Quarterly Result25 May 2026, 06:02 pm
Fredun Pharma FY26: Revenue Up 40%, EBITDA Surges 72%
AI Summary
Fredun Pharmaceuticals Ltd reported robust FY26 results with revenue jumping 40% to ₹639 Cr, EBITDA surging 72% to ₹94.79 Cr, and profit rising ~60% to ₹33.21 Cr YoY. The company's performance reflects growth across generics, cosmeceuticals, nutraceuticals, mobility, and animal healthcare products. The Board recommended a dividend of ₹0.70 per share and a bonus share issuance in the ratio of 2:1. Fredun is expanding its Palghar facility and has received a credit rating upgrade to IVR BBB+.
Key Highlights
- FY26 revenue increased by 40% YoY to ₹639 Cr.
- EBITDA jumped 72% YoY to ~₹95 Cr, with margins expanding to 14.8%.
- PAT surged ~60% YoY to ₹33 Cr.
- Bonus shares recommended in the ratio of 2:1.
- Credit rating upgraded to IVR BBB+ (Stable) from IVR BBB (Stable).
Price Impact
More from FREDUN